Agreement permits GRI to actively promote Alpha Innotech's range of gel documentation and analysis systems through its molecular biology sales division
GRI, the independent supplier of biotechnology instrumentation, has signed a sole UK agency agreement with Alpha Innotech.
The agreement permits GRI to actively promote Alpha Innotech's range of gel documentation and analysis systems through its molecular biology sales division.
The addition of Alpha Innotech and its range of global market leading gel imaging products into GRI's product portfolio ensures that the UK biotech industry has access to the latest in cutting edge technology, backed by customer and product support unrivalled in today's market, says GRI.
Alpha Innotech is a provider of integrated discovery products for genomic research and drug discovery with core expertise in quantitative imaging, informatics, and molecular biology.
It has over 15,000 customers worldwide, with direct offices and distribution in over 35 countries.
Alpha Innotech has core competencies in imaging, informatics, and molecular biology applied to the life science fields of genomics, functional genomics, and proteomics.
As such, expertise in excitation, signal detection, image analysis, and data management technology is synergistically integrated to deliver best in class performance.
Simon Nicklin, sales and marketing director for GRI said, "As a leading supplier to the ever-developing UK biotechnology market place, we are very pleased to represent a company and product line as prestigious as Alpha Innotech.
We believe that with our experience, knowledge and relationships within UK molecular biology, that this relationship will be of true benefit to all parties, especially our customers". GRI's molecular biology division will have sole UK responsibility for sales and support of Alpha Innotech's complete range of gel documentation systems.
These systems offer complete solutions for fluorescence and chemiluminescence analysis applications and are available immediately from GRI.
